Literature DB >> 18299417

Comparison of antimicrobial resistance profiles among extended-spectrum-beta-lactamase-producing and acquired AmpC beta-lactamase-producing Escherichia coli isolates from Canadian intensive care units.

Patricia J Baudry1, Kim Nichol, Melanie DeCorby, Laura Mataseje, Michael R Mulvey, Daryl J Hoban, George G Zhanel.   

Abstract

Resistance profiles were compared among 18 extended-spectrum-beta-lactamase-producing (ESBL) and 27 acquired AmpC beta-lactamase-producing Escherichia coli isolates collected from Canadian intensive care units from 2005 to 2006. ESBL-producing E. coli isolates were more likely to be gentamicin resistant (P < 0.03), fluoroquinolone resistant (P < 0.0001), and multidrug resistant (P < 0.0001) than AmpC-producing E. coli isolates.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18299417      PMCID： PMC2346658          DOI： 10.1128/AAC.01176-07

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

1.  Detection of plasmid-mediated AmpC beta-lactamase genes in clinical isolates by using multiplex PCR.

Authors:  F Javier Pérez-Pérez; Nancy D Hanson
Journal:  J Clin Microbiol       Date:  2002-06       Impact factor: 5.948

2.  Occurrence of plasmidic AmpC type beta-lactamase-mediated resistance in Escherichia coli: report from the SENTRY Antimicrobial Surveillance Program (North America, 2004).

Authors:  Lalitagauri M Deshpande; Ronald N Jones; Thomas R Fritsche; Helio S Sader
Journal:  Int J Antimicrob Agents       Date:  2006-11-16       Impact factor: 5.283

3.  Wide geographic spread of diverse acquired AmpC beta-lactamases among Escherichia coli and Klebsiella spp. in the UK and Ireland.

Authors:  Neil Woodford; Suganya Reddy; Elizabeth J Fagan; Robert L R Hill; Katie L Hopkins; Mary E Kaufmann; James Kistler; Marie-France I Palepou; Rachel Pike; M Elaina Ward; John Cheesbrough; David M Livermore
Journal:  J Antimicrob Chemother       Date:  2006-11-16       Impact factor: 5.790

4.  Molecular characterization of cefoxitin-resistant Escherichia coli from Canadian hospitals.

Authors:  Michael R Mulvey; Elizabeth Bryce; David A Boyd; Marianna Ofner-Agostini; Allison M Land; Andrew E Simor; Shirley Paton
Journal:  Antimicrob Agents Chemother       Date:  2005-01       Impact factor: 5.191

5.  Characterisation of CTX-M and AmpC genes in human isolates of Escherichia coli identified between 1995 and 2003 in England and Wales.

Authors:  K L Hopkins; M J Batchelor; E Liebana; A P Deheer-Graham; E J Threlfall
Journal:  Int J Antimicrob Agents       Date:  2006-08-01       Impact factor: 5.283

6.  Characterization of clinical isolates of Klebsiella pneumoniae from 19 laboratories using the National Committee for Clinical Laboratory Standards extended-spectrum beta-lactamase detection methods.

Authors:  C D Steward; J K Rasheed; S K Hubert; J W Biddle; P M Raney; G J Anderson; P P Williams; K L Brittain; A Oliver; J E McGowan; F C Tenover
Journal:  J Clin Microbiol       Date:  2001-08       Impact factor: 5.948

7.  Complete nucleotide sequence of a 92-kilobase plasmid harboring the CTX-M-15 extended-spectrum beta-lactamase involved in an outbreak in long-term-care facilities in Toronto, Canada.

Authors:  David A Boyd; Shaun Tyler; Sara Christianson; Allison McGeer; Matthew P Muller; Barbara M Willey; Elizabeth Bryce; Michael Gardam; Patrice Nordmann; Michael R Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2004-10       Impact factor: 5.191

8.  Molecular epidemiology of CTX-M-producing Escherichia coli in the Calgary Health Region: emergence of CTX-M-15-producing isolates.

Authors:  Johann D D Pitout; Deirdre L Church; Daniel B Gregson; Barbara L Chow; Melissa McCracken; Michael R Mulvey; Kevin B Laupland
Journal:  Antimicrob Agents Chemother       Date:  2007-02-05       Impact factor: 5.191

9.  Ambler class A extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella spp. in Canadian hospitals.

Authors:  Michael R Mulvey; Elizabeth Bryce; David Boyd; Marianna Ofner-Agostini; Sara Christianson; Andrew E Simor; Shirley Paton
Journal:  Antimicrob Agents Chemother       Date:  2004-04       Impact factor: 5.191

10.  Population-based laboratory surveillance for AmpC beta-lactamase-producing Escherichia coli, Calgary.

Authors:  Johann D D Pitout; Daniel B Gregson; Deirdre L Church; Kevin B Laupland
Journal:  Emerg Infect Dis       Date:  2007-03       Impact factor: 6.883
View more
  15 in total

1.  Clinical significance of infections caused by plasmid-mediated AmpC β-lactamases and extended-spectrum β-lactamase-producing Escherichia coli.

Authors:  H S Cheong; K S Ko; C-I Kang; D R Chung; K R Peck; J-H Song
Journal:  Infection       Date:  2012-09-27       Impact factor: 3.553

Review 2.  Clinical management of infections caused by multidrug-resistant Enterobacteriaceae.

Authors:  Mercedes Delgado-Valverde; Jesús Sojo-Dorado; Alvaro Pascual; Jesús Rodríguez-Baño
Journal:  Ther Adv Infect Dis       Date:  2013-04

3.  Activity of NXL104 in combination with beta-lactams against genetically characterized Escherichia coli and Klebsiella pneumoniae isolates producing class A extended-spectrum beta-lactamases and class C beta-lactamases.

Authors:  P R S Lagacé-Wiens; F Tailor; P Simner; M DeCorby; J A Karlowsky; A Walkty; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-02-28       Impact factor: 5.191

4.  Characterization of blaCMY-2 plasmids in Salmonella and Escherichia coli isolates from food animals in Canada.

Authors:  Laura C Martin; Emily K Weir; Cornelis Poppe; Richard J Reid-Smith; Patrick Boerlin
Journal:  Appl Environ Microbiol       Date:  2011-12-09       Impact factor: 4.792

5.  In vitro activity of ceftaroline against gram-positive and gram-negative pathogens isolated from patients in Canadian hospitals in 2009.

Authors:  James A Karlowsky; Heather J Adam; Melanie R Decorby; Philippe R S Lagacé-Wiens; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2011-03-14       Impact factor: 5.191

6.  Prevalence of antimicrobial-resistant pathogens in Canadian hospitals: results of the Canadian Ward Surveillance Study (CANWARD 2008).

Authors:  George G Zhanel; Melanie DeCorby; Heather Adam; Michael R Mulvey; Melissa McCracken; Philippe Lagacé-Wiens; Kimberly A Nichol; Aleksandra Wierzbowski; Patricia J Baudry; Franil Tailor; James A Karlowsky; Andrew Walkty; Frank Schweizer; Jack Johnson; Daryl J Hoban
Journal:  Antimicrob Agents Chemother       Date:  2010-08-30       Impact factor: 5.191

7.  Characterization of cefoxitin-resistant Escherichia coli isolates from recreational beaches and private drinking water in Canada between 2004 and 2006.

Authors:  L F Mataseje; N Neumann; B Crago; P Baudry; G G Zhanel; M Louie; M R Mulvey
Journal:  Antimicrob Agents Chemother       Date:  2009-04-27       Impact factor: 5.191

8.  Differences in antimicrobial susceptibility in Escherichia coli from Canadian intensive care units based on regional and demographic variables.

Authors:  Philippe Rs Lagacé-Wiens; Melanie R Decorby; Patricia J Baudry; Daryl J Hoban; James A Karlowsky; George G Zhanel
Journal:  Can J Infect Dis Med Microbiol       Date:  2008-07       Impact factor: 2.471

9.  In vitro activity of ceftaroline-avibactam against gram-negative and gram-positive pathogens isolated from patients in Canadian hospitals from 2010 to 2012: results from the CANWARD surveillance study.

Authors:  James A Karlowsky; Heather J Adam; Melanie R Baxter; Philippe R S Lagacé-Wiens; Andrew J Walkty; Daryl J Hoban; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2013-08-26       Impact factor: 5.191

10.  On-Farm Anaerobic Digestion of Dairy Manure Reduces the Abundance of Antibiotic Resistance-Associated Gene Targets and the Potential for Plasmid Transfer.

Authors:  Tam T Tran; Andrew Scott; Yuan-Ching Tien; Roger Murray; Patrick Boerlin; David L Pearl; Kira Liu; James Robertson; John H E Nash; Edward Topp
Journal:  Appl Environ Microbiol       Date:  2021-06-25       Impact factor: 4.792
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.